Johann Poetzl
Overview
Explore the profile of Johann Poetzl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
89
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Poetzl J
Bioanalysis
. 2025 Feb;
17(5):355-358.
PMID: 39901692
Immunogenicity knowledge and the analytical capabilities to characterize molecules have evolved within the last decade. This creates opportunities in Biosimilar development by applying new strategies to demonstrate similarity between a...
2.
Tounekti O, Prior S, Wassmer S, Xu J, Wong A, Fang X, et al.
Bioanalysis
. 2025 Jan;
17(3):105-149.
PMID: 39862111
The 18 Workshop on Recent Issues in Bioanalysis (18 WRIB) took place in San Antonio, TX, USA on May 6-10, 2024. Over 1100 professionals representing pharma/biotech companies, CROs, and multiple...
3.
Chamberlain P, Hemmer B, Hofler J, Wessels H, von Richter O, Hornuss C, et al.
Front Immunol
. 2025 Jan;
15:1414304.
PMID: 39749348
Background: Biosimilar natalizumab (biosim-NTZ) is the first biosimilar monoclonal antibody of reference natalizumab (ref-NTZ) for treatment of relapsing forms of multiple sclerosis (MS). Within the totality of evidence for demonstration...
4.
Schalk F, Guerrieri D, Poetzl J, van de Merbel N
Bioanalysis
. 2024 Dec;
17(2):87-98.
PMID: 39690968
Background: Commonly, ligand-binding platforms are being used for immunogenicity assessment, but with the recent advent of liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) for protein quantification, this technology has...
5.
Lemke L, Blauvelt A, Bruckmann I, Cohen H, Fan J, Guerrieri D, et al.
Expert Opin Biol Ther
. 2024 Nov;
24(12):1375-1385.
PMID: 39545451
Background: To support an interchangeability designation for Sandoz adalimumab biosimilar (GP2017), antidrug antibody (ADA) signal-to-noise (S/N) ratios were assessed in the GP2017 ADACCESS trial to directly assess potential changes in...
6.
Selmaj K, Roth K, Hofler J, Vitzithum K, Derlacz R, von Richter O, et al.
BioDrugs
. 2024 Sep;
38(6):755-767.
PMID: 39343860
A biosimilar medicine is a successor to a reference ('originator'/'original-brand') biologic medicine brought to market once the patent and exclusive marketing rights for the reference have expired. Biosimilar natalizumab (PB006...
7.
Vogg B, Poetzl J, Schwebig A, Sekhar S, Kivitz A, Krivtsova N, et al.
Clin Ther
. 2024 Sep;
46(11):916-926.
PMID: 39294041
Purpose: Sandoz biosimilar denosumab (GP2411 [SDZ-deno]; Jubbonti/Wyost) is approved by the US FDA, EMA and Health Canada for all indications of reference denosumab (REF-deno; Prolia/Xgeva), a fully human IgG2κ monoclonal...
8.
Jeka S, Dokoupilova E, Kivitz A, Zuchowski P, Vogg B, Krivtsova N, et al.
J Bone Miner Res
. 2024 Mar;
39(3):202-210.
PMID: 38477751
Denosumab is a monoclonal antibody used to reduce risk of fractures in osteoporosis. ROSALIA was a multicenter, double-blind, randomized, integrated phase I/phase III study comparing the efficacy, pharmacokinetics (PK), pharmacodynamics...
9.
Mora J, Palmer R, Wagner L, Wu B, Partridge M, Meena , et al.
Bioanalysis
. 2024 Feb;
16(7):77-119.
PMID: 38389403
The 17 Workshop on Recent Issues in Bioanalysis (17 WRIB) took place in Orlando, FL, USA on June 19-23, 2023. Over 1000 professionals representing pharma/biotech companies, CROs, and multiple regulatory...
10.
Vogg B, Poetzl J, El Galta R, Fuhr R, Schwebig A, Sekhar S
Expert Opin Biol Ther
. 2024 Jan;
24(1-2):91-100.
PMID: 38269652
Background: This Phase I study compared the pharmacokinetic (PK) and pharmacodynamic (PD) similarity of GP2411 proposed denosumab biosimilar to reference denosumab (a monoclonal antibody for specific pro-resorptive conditions). Research Design...